- Migraine affects more than 1 million people around the world.
- Experts expect regulators in the United States to approve a new zavegepant nasal spray for the treatment of migraine headaches.
- A phase 2/3 clinical trial for zavegepant reported users experienced statistically significant pain relief in as early as 15 minutes.
- Because people take the drug as a nasal spray, experts state it will help the medication act more quickly and provide an alternative for people who have migraine headaches with nausea.
Migraine affects
Although there is currently no cure for migraine, doctors can prescribe medications to help prevent or stop these painful headaches from occurring.
Physicians can also assist people with identifying and avoiding migraine triggers.
Now, doctors are waiting for the U.S. Food and Drug Administration (FDA) to approve a new zavegepant nasal spray for the treatment of migraine.
The drug’s manufacturer Biohaven Pharmaceutical Holding Company had previously reported what it described as positive results from its phase 2/3 clinical trial. Pfizer acquired Biohaven in October 2022.
The
Migraine is a neurological condition different from a headache.
Migraine are severe and recurrent and can last anywhere from a few hours to several days.
Migraine symptoms can happen before, during, and after an episode. These can include:
“Migraine is characterized by debilitating attacks lasting four to 72 hours with multiple symptoms, including pulsating headaches of moderate to severe pain intensity that can be associated with nausea or vomiting, and/or sensitivity to sound (
Read the full article here